Assessing the necessity of chimpanzee experimentation.

A. Knight

DOI: https://doi.org/10.14573/altex.2012.1.093

2012-02-01

ALTEX

Abstract:Assessing the Necessity (Altevogt et al., 2011a). the report responded to a National Institutes of Health (NIH) request for expert guidance on the scientific need to use chimpanzees within such research. the IOM committee concluded that most current use of chimpanzees for biomedical research – including RSV vaccine, therapeutic hepatitis C (HCV) vaccine, and HCV antiviral drug development – is not warranted, with the possible exception of two very limited research uses: for the production of mono-clonal antibodies (mAbs) and the development of prophylactic HCV vaccines. The committee stated, " it will be very difficult to defend the necessity of nearly all current biomedical research on chimpanzees. " Yet it stopped short of recommending an outright ban (Altevogt et al., 2011b). Even this limited support of invasive chimpanzee research is questionable, however. The committee noted that, " Production of monoclonal antibodies after immunization in other species or through in vitro synthetic methods is equally powerful for the generation of such reagents. " They also noted four methods currently in use that lessen the need for safety tests of mAbs in chimpanzees. However, they still supported the use of chimpanzees for mAbs developed using older technologies, although they expected such use would cease within five years. Yet, it would seem far more ethical, and could also potentially yield safety, efficacy and financial benefits, if the most modern technologies were used without further delay. As Bettauer (2011) noted with respect to chimpanzee use in mAb research and drug development, " Available alternatives, together with ethical and economic reasons, suggest that the use of the chimpanzee in this manner may not be necessary or appropriate. " The committee noted that HCV antiviral drug and therapeutic vaccine development does not require the use of chimpanzees, but were uncertain about their necessity for the development of prophylactic vaccines. However, they also noted the existence of alternative research strategies: " studies in consenting individuals at high risk for natural HCV infection can be ethically done provided that these vaccines are first shown to be safe and immunogenic in experimental animals, such as mice and nonhu-man primates. " After reviewing 109 chimpanzee HCV studies, Bettauer (2010) found considerable problems with statistical validity, repeatability, and the biological relevance of the chimpanzee model. Bailey (2010) similarly found that, " claims of the necessity of chimpanzees in historical and future hepatitis C research are exaggerated and unjustifiable, respectively. " He …